SynthesisBMJ open respiratory research2025
Risk of long covid in patients with pre-existing chronic respiratory diseases: a systematic review and meta-analysis.
Synthesis in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Clinical and Immunovirological Characteristics Associated with Cardiovascular Dysautonomia in Long COVID.Journal of clinical medicine · 2026Article
- Long-term health outcomes in elderly COPD patients with long COVID: a 2-year prospective cohort study.Respiratory research · 2026Article
- Post-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up.Journal of clinical medicine · 2026Review
- Long COVID following SARS-CoV-2 infection during pregnancy: An observational study in a large Italian hospital during the COVID-19 pandemic.Acta obstetricia et gynecologica Scandinavica · 2026Observational
- Article
- Investigation of Biomarkers in Allergic Patients with Long COVID.Journal of personalized medicine · 2026Article
- Bidirectional associations between chronic diseases and Long COVID: a population-based cohort and interrupted time-series analysis.Frontiers in public health · 2026Article
- Global Trends of Cognition-Targeted Interventions in Chronic Lung Disease: A Bibliometric and Visualized Analysis.International journal of chronic obstructive pulmonary disease · 2026Review
- Long COVID in adults - a current review of the long-term health effects following SARS-CoV-2 infection.Journal of health monitoring · 2026Article
- COVID-19 symptom duration: evidence from a survey of infected workers in Tokyo.Frontiers in public health · 2026Article
- One-year healthcare trajectories after COVID-19 hospitalisation in patients with chronic respiratory diseases: a nationwide study.BMJ open respiratory research · 2025Article
- Article
- Non-Viral Therapy in COVID-19: Where Are We Standing? How Our Experience with COVID May Help Us Develop Cell Therapies for Long COVID Patients.Biomedicines · 2025Review
- Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs.Journal of clinical medicine · 2025Review
- Management of SARS-CoV-2 Infection-Clinical Practice Guidelines of the Polish Association of Epidemiologists and Infectiologists, for 2025.Journal of clinical medicine · 2025Review
- Japanese nationwide survey to track the impact of long COVID over 3 years.Environmental health and preventive medicine · 2025Article
- Long COVID in Elderly COPD Patients: Clinical Features, Pulmonary Function Decline, and Proteomic Insights.International journal of chronic obstructive pulmonary disease · 2025Article
- Jing-Si Herbal Tea as a multitargeted complementary therapy: Evidence from preclinical and clinical studies.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn estimated 10-30% of people with COVID-19 experience debilitating long-term symptoms or long covid. Underlying health conditions associated with chronic inflammation may increase the risk of long covid.
methodsWe conducted a systematic review and meta-analysis to examine whether long covid risk was altered by pre-existing asthma or chronic obstructive pulmonary disease (COPD) in adults. We identified studies by searching the PubMed and Embase databases from inception to 13 September 2024. We excluded studies that focused on children or defined long covid only in terms of respiratory symptoms. We used random-effects, restricted maximum likelihood models to analyse data pooled from 51 studies, which included 43 analyses of asthma and 30 analyses of COPD. The risk of bias was assessed using a ROBINS-E table.
resultsWe found 41% increased odds of long covid with pre-existing asthma (95% CI 1.29 to 1.54); pre-existing COPD was associated with 32% increased odds (95% CI 1.16 to 1.51). Pre-existing asthma, but not COPD, was associated with increased odds of long covid-associated fatigue. We observed heterogeneity in the results of studies of asthma related to hospitalisation status. Potential confounding and inconsistent measurement of exposure and outcome variables were among the identified limitations.
conclusionsOur findings support the hypothesis that pre-existing asthma and COPD increase the risk of long covid, including chronic fatigue outcomes in patients with asthma. Because COVID-19 targets the respiratory tract, these inflammatory conditions of the lower respiratory tract could provide mechanistic clues to a common pathway for the development of long-term sequelae in patients with long covid.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.